Gilead Sciences GILD Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $29.44B+2.4% | $28.75B+6.0% | $27.12B-0.6% | $27.28B-0.1% | ||
| $6.23B-0.3% | $6.25B-3.8% | $6.5B+14.9% | $5.66B-14.3% | ||
| $23.21B+3.1% | $22.5B+9.1% | $20.62B-4.7% | $21.62B+4.4% | ||
| 78.8%+0.6pp | 78.3%+2.2pp | 76%-3.2pp | 79.3%+3.4pp | ||
| $5.77B-5.2% | $6.09B0.0% | $6.09B+7.4% | $5.67B+8.1% | ||
| $19.42B-28.3% | $27.09B+38.8% | $19.51B-2.2% | $19.95B+14.7% | ||
| $10.02B+503% | $1.66B-78.1% | $7.61B+3.8% | $7.33B-26.1% | ||
| 34%+28.3pp | 5.8%-22.3pp | 28%+1.2pp | 26.9%-9.5pp | ||
| $1.03B+4.8% | $978M+3.6% | $944M+1.0% | $935M-6.6% | ||
| $798M— | —— | $199M+134% | -$581M+16.5% | ||
| $9.8B+1,320% | $690M-89.9% | $6.86B+18.0% | $5.81B-29.8% | ||
| $1.39B+559% | $211M-83.1% | $1.25B0.0% | $1.25B-39.9% | ||
| $8.51B+1,673% | $480M-91.5% | $5.66B+23.3% | $4.59B-26.2% | ||
| 28.9%+27.2pp | 1.7%-19.2pp | 20.9%+4.1pp | 16.8%-6.0pp | ||
| $6.77+1,730% | $0.37-91.8% | $4.49+23.0% | $3.65-26.0% | ||
| $6.85+1,751% | $0.37-91.9% | $4.55+24.0% | $3.67-26.0% | ||
| 5B+0.3% | 5B-0.5% | 5B-0.2% | 5B0.0% | ||
| 5B-0.2% | 5B-0.1% | 5B-0.6% | 5B0.0% | ||
| $1.02B-78.1% | $4.67B+305% | $1.16B+22.4% | $944M+0.5% | ||
| $2.39B+0.2% | $2.39B+2.0% | $2.34B+31.4% | $1.78B+3.4% | ||
| —— | -$1.84B-91.7% | -$962M+38.0% | -$1.55B-1,238% | ||
| $370M-2.9% | $381M+7.6% | $354M+9.6% | $323M-1.8% | ||
| —— | —— | -$347M-254% | $226M— | ||
| —— | -$139M— | —— | $406M— | ||
| —— | $108M-76.4% | $458M— | —— | ||
| -$2.11B— | —— | -$1.77B— | —— | ||
| $1.04B+143% | $426M-49.4% | $842M+172% | $310M+2,918% | ||
| $311M+20.1% | $259M— | —— | $146M— | ||
| -$7.75B— | —— | -$5.13B+20.8% | -$6.47B+27.1% | ||
| -$4.79B-39.0% | -$3.45B-52.3% | -$2.27B+8.2% | -$2.47B+21.2% | ||
| $10.02B-7.5% | $10.83B+35.2% | $8.01B-11.8% | $9.07B-20.3% | ||
| -$480M-36.0% | -$353M+57.3% | -$826M-5.9% | -$780M-30.7% | ||
| —— | -$58M-5,900% | $1M— | —— | ||
| $1.92B+67.1% | $1.15B+15.0% | $1B-28.4% | $1.4B+156% | ||
| $4B+2.2% | $3.92B+2.9% | $3.81B+2.7% | $3.71B+2.9% | ||
| $3.65B— | —— | $1.93B+9.0% | $1.77B-49.7% | ||
| $1.07B-77.9% | $4.84B+320% | $1.15B-35.9% | $1.8B+13.4% | ||
| $563M+7.6% | $523M-10.6% | $585M-19.6% | $728M+25.7% | ||
| $408M-3.3% | $422M+81.9% | $232M-24.9% | $309M+82.8% | ||
| $55M— | —— | $1.33B-16.1% | $1.59B-27.1% | ||
| -$440M-56.6% | -$281M-0.7% | -$279M-61.3% | -$173M-19.3% | ||
| $854M— | —— | $510M+23.8% | $412M-43.6% | ||
| $1.79B-9.2% | $1.97B-12.4% | $2.25B— | —— | ||
| $5.8B-1.8% | $5.91B+3.3% | $5.72B+14.9% | $4.98B+8.1% | ||
| $29.44B+2.4% | $28.75B+6.0% | $27.12B-0.6% | $27.28B-0.1% | ||
| $894M+7.1% | $835M+9.0% | $766M+20.3% | $637M+0.3% | ||
| $10.39B+409% | $2.04B-78.9% | $9.7B+7.9% | $8.99B-12.3% | ||
| 35.3%+28.2pp | 7.1%-28.7pp | 35.8%+2.8pp | 32.9%-4.6pp | ||
| $10.02B+503% | $1.66B-78.1% | $7.61B+3.8% | $7.33B-26.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gilead Sciences's revenue?
- Gilead Sciences (GILD) generated $29.7B in revenue over the trailing twelve months, up 3.5% year over year.
- Is Gilead Sciences profitable?
- Gilead Sciences reported $9.2B in net income over the trailing twelve months, a 31.0% net margin.
- What are Gilead Sciences's profit margins?
- Gross margin is 79.4% and operating margin is 34.9%, with a 31.0% net margin.
- What is Gilead Sciences's earnings per share?
- Gilead Sciences's diluted EPS over the trailing twelve months is $7.34.
- Where does Gilead Sciences's income statement data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
